Skip to main content

Table 1 Baseline demographic and clinical characteristics of patients with AS: comparison of patients entering double-blind and open-label extension study periods

From: Physical function, disease activity, and health-related quality-of-life outcomes after 3 years of adalimumab treatment in patients with ankylosing spondylitis

 

Week 24 of ATLAS (n = 315)

Open-label extension (n = 288)

P value a

Age, years

42.2 ± 11.57

42.4 ± 11.65

0.848

Male, n (%)

236 (74.9)

219 (76.0)

0.777

White, n (%)

301 (95.6)

276 (95.8)

1.000

Disease duration, years

10.9 ± 9.47

10.9 ± 9.43

0.953

BASDAI score, 0–10 cm

6.3 ± 1.69

6.3 ± 1.70

0.997

BASFI score, 0–10 cm

5.4 ± 2.21

5.4 ± 2.19

0.900

SF-36 PCS, 0–50

32.5 ± 7.98

32.4 ± 8.00

0.846

SF-36 MCS, 0–50

43.7 ± 11.57

44.0 ± 11.48

0.804

SF-36 domain scales

   Physical Function

47.1 ± 22.08

46.8 ± 22.49

0.893

   Role–Physical

20.3 ± 30.02

20.9 ± 30.25

0.808

   Bodily Pain

55.9 ± 25.06

55.9 ± 25.08

0.979

   General Health

42.6 ± 19.82

42.6 ± 20.06

0.997

   Vitality

31.1 ± 16.12

30.9 ± 16.12

0.875

   Social Function

33.1 ± 17.49

32.9 ± 17.30

0.895

   Role–Emotional

54.4 ± 42.98

56.1 ± 42.90

0.641

   Mental Health

61.7 ± 19.19

61.8 ± 19.17

0.952

ASQOL, 0–18

10.3 ± 4.29

10.3 ± 4.29

0.945

  1. Data are mean ± standard deviation unless otherwise noted.
  2. aP-values for comparing means based on two-sample paired Student t-tests; P-values for comparing percentages based on Fisher's exact tests.
  3. AS = ankylosing spondylitis; ASQOL = AS Quality of Life Questionnaire; ATLAS = Adalimumab Trial Evaluating Long-Term Efficacy and Safety in AS; BASDAI = Bath AS Disease Activity Index; BASFI = Bath AS Functional Index; HRQOL = health-related quality-of-life; MCS = Mental Component Summary; PCS = Physical Component Summary; SF-36 = Short Form-36 Health Survey.